Letybo (letibotulinumtoxin)
Research Synopsis
- Letybo (letibotulinumtoxin) is a new neurotoxin derived from Clostridium botulinum, primarily studied for its efficacy in cosmetic treatments such as reducing glabellar lines.
- A Phase 3 clinical trial with 355 participants revealed that 78.6% of subjects treated with Letybo showed significant improvement in glabellar line severity after four weeks, contrasting sharply with 0% in the placebo group, indicating strong effectiveness.
- Research indicates that botulinum toxin type A can effectively reduce spasticity, particularly in children with cerebral palsy, emphasizing the importance of injection frequency and dosage in treatment outcomes.
- Comparatively, studies on different types of botulinum toxins (including Letybo) suggest variations in fibroblast contraction, which may influence clinical results in facial lifting procedures.
- Newer botulinum toxins like Letybo are gaining traction in dermatology, providing advantages such as longer-lasting results and quicker effects compared to traditional options.
- Evaluations of the potency of various botulinum toxins revealed differences in activity and protein levels, underscoring the importance of accurate assessment methods, including those applicable to Letybo.
- The general sentiment surrounding Letybo is positive, particularly regarding its safety and effectiveness, making it a noteworthy option for aesthetic treatments.
- Continued research and development of neurotoxin treatments like Letybo highlight its potential within therapeutic and cosmetic frameworks, driving interest among practitioners seeking improved patient outcomes.
- Further studies may focus on long-term effects and comparative advantages of Letybo against older formulations, reinforcing its role in the evolving landscape of cosmetic medicine.
Letybo (letibotulinumtoxin)
Efficacy of Repeated Botulinum Toxin Type A Injections for Spastic Equinus in Children with Cerebral Palsy-A Secondary Analysis of the Randomized Clinical Trial.
London, UK
2 hours ago
1 Received
- Botulinum toxin A is a key treatment for reducing spasticity in children with cerebral palsy, influenced by factors like dosage, muscle selection, and age.
- A phase III clinical trial involving 144 children compared the effects of two types of botulinum toxin A on dynamic equinus and assessed how repeated injections impacted treatment outcomes.
- Results showed that a single injection significantly improved motor function after 3 months, while fewer injections before the study led to better gait outcomes at 6 months compared to those with multiple prior injections.
$100 - $150
Hourly Rate
The effect of botulinum toxin type A in different dilution on the contraction of fibroblast-In vitro study.
London, UK
2 hours ago
1 Received
- Botulinum toxin type A (BoNT-A) has been studied for its potential to lift and remodel skin tissues through intradermal injection, which is hypothesized to produce a lifting effect on the midface.
- The study evaluated various types of BoNT-A (ONA, ABO, PRABO, INCO, and LETI) to see how they affect the contraction of human dermal fibroblasts at different dilutions within a 12-hour period.
- Results showed that while ONA did not alter fibroblast length, other preparations like ABO, PRABO, INCO, and LETI demonstrated varying degrees of contraction depending on dilution, influencing clinical outcomes in facial lifting procedures.
$100 - $150
Hourly Rate
Updates on Botulinum Neurotoxins in Dermatology.
London, UK
2 hours ago
1 Received
- Botulinum neurotoxin (BoNT) injections are the most popular non-surgical cosmetic treatment and are gaining attention from practitioners worldwide.
- The article discusses new botulinum toxins in development or nearing market approval in the USA and Canada, such as daxibotulinumtoxin A, prabotulinumtoxin A, letibotulinumtoxin A, and botulinum toxin E.
- These new neurotoxins, while similar in effectiveness, offer unique benefits like longer-lasting results, fewer animal-derived components, and quicker effects with shorter durations.
$100 - $150
Hourly Rate
Practical Application of Novel Test Methods to Evaluate the Potency of Botulinum Toxin: A Comparison Analysis among Widely Used Products in Korea.
London, UK
2 hours ago
1 Received
- This study investigates the safe and effective dosing of botulinum neurotoxins (BoNTs), which is essential for their therapeutic use, by comparing potency measurement methods.
- Four types of BoNTs (prabotulinumtoxin A, onabotulinumtoxin A, neubotulinumtoxin A, and letibotulinumtoxin A) are evaluated using various assays, including the LD50, enzyme-linked immunosorbent assay (ELISA), fluorescence resonance energy transfer (FRET), and surface plasmon resonance (SPR).
- Results highlighted differences in protein levels and cleavage activity across BoNT types, suggesting that the SPR method may be particularly useful for accurately assessing neurotoxin potency
$100 - $150
Hourly Rate
Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study.
London, UK
2 hours ago
1 Received
- Letibotulinumtoxin A, a new neurotoxin derived from Clostridium botulinum, aims to treat glabellar lines (frown lines between the eyebrows) with its safety and efficacy evaluated through a Phase III clinical trial involving 355 participants.
- In the trial, 78.6% of subjects treated with letibotulinumtoxin A showed improvement in glabellar line severity at 4 weeks, compared to 0% in the placebo group, indicating its effectiveness.
- Overall, the study concluded that letibotulinumtoxin A is both effective and well-tolerated for reducing glabellar line severity.
$100 - $150
Hourly Rate